Australian biotech market watch 30/09/09
Wednesday, 30 September, 2009
A rather flat day on the markets on this last day of September, with the All Ordinaries sitting around the 4,746 mark as of 2:00pm this afternoon and the heath care indices following suit.
Of the Big Three, bionic ear pioneer, Cochlear (ASX:COH) is up a modest 63c to $67.39 and ResMed (ASX:RMD) remains flat at $5.17. CSL (ASX:CSL), which has been in the news of late with controversy over the national rollout of H1N1 vaccines, is down 36c, or 1.1% to $33.39.
Ansell (ASX:ANN) managed to lift by 1.62% to $10.06 in low volume trading after a rather flat couple of weeks.
The only other movers are Fisher & Paykel Healthcare, up 1.9% to $2.69, recovering some of the losses it's experienced since its high of $2.80 at the beginning of September, and Sonic Healthcare, up 38c to $14.24, which is 3.8% for the week.
Eye disease specialist, pSivida (ASX:PVA), dropped 57c to $4.95 after it announced early safety and efficacy results of its drug Iluvien, which proved "promising".
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
